To increase the number of tumor-reactive T cells, approaches are undertaken to either transfer TCR transgenic T cells into patients or by isolation and expansion of T cells which are most likely to be enriched for tumor-reactive T cells using the expression of the activation markers CD137, PD-1, or CD39 to select the T cells (190–193). Here, ENTPD1 is linked to neoplasm.